| Literature DB >> 32781984 |
Derek Hazard1,2, Klaus Kaier3,4, Maja von Cube3,4, Marlon Grodd3,4, Lars Bugiera3,4, Jerome Lambert3,5, Martin Wolkewitz3,4.
Abstract
BACKGROUND: The clinical progress of patients hospitalized due to COVID-19 is often associated with severe pneumonia which may require intensive care, invasive ventilation, or extracorporeal membrane oxygenation (ECMO). The length of intensive care and the duration of these supportive therapies are clinically relevant outcomes. From the statistical perspective, these quantities are challenging to estimate due to episodes being time-dependent and potentially multiple, as well as being determined by the competing, terminal events of discharge alive and death.Entities:
Keywords: Competing risks; Length of stay; Mechanical ventilation; Multistate model; SARS-CoV-2
Mesh:
Substances:
Year: 2020 PMID: 32781984 PMCID: PMC7507941 DOI: 10.1186/s12874-020-01082-z
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
Fig. 1Multistate Model. Multistate model for patients admitted to the ICU with severe COVID-19. The boxes represent potential states for an ICU patient. The arrows represent the potential transitions among the states
Example structure of data set. Portion of data set from example 1 as extracted from Bhatraju et al. [8]. Full data set provided in Additional file 2. id: patient id, from: state entered at time ‘entry’, to: state entered at time ‘exit’, entry: time of entry into state ‘from’, exit: time of entry into state ‘to’
| id | from | to | entry | exit |
|---|---|---|---|---|
| 1 | 1 | 2 | 0 | 5 |
| 1 | 2 | 1 | 5 | 16 |
| 1 | 1 | 0 | 16 | 25 |
| 2 | 1 | 4 | 0 | 1 |
| 3 | 2 | 1 | 0 | 12 |
| 3 | 1 | 3 | 12 | 15 |
Example 1 Results. Predicted sojourn times and mortality for patients in data example from Bhatraju et al. [8] at 28 days of follow-up. Start: time of ICU admission, Non-MV: ICU without MV and acute care, MV: ICU with MV, (): 95% confidence interval for duration estimates, (): standard error for risk estimates
| 24 critically-ill COVID-19 patients in Seattle, USA (Bhatraju et al.), results at day 28 | ||||
|---|---|---|---|---|
| Non-MV Duration in Days | MV Duration in Days | Total Length of ICU Stay in Days | Death Risk | |
| Start Non-MV | 9.82 (5.84, 14.42) | 4.34 (1.65, 7.7) | 14.16 (7.49, 22.12) | 47.8% (10.5) |
| Start MV | 3.84 (1.12, 7.44) | 12.25 (9.00, 16.03) | 16.09 (10.12, 23.47) | 54.4% (10.7) |
| Full Cohort | 7.08 (4.00, 10.48) | 7.97 (5.29, 11.18) | 15.05 (9.29, 21.66) | 50.8% (10.6) |
Fig. 2Example 1 Plot. Stacked probability plot for the data from example 1 [8] using the model in Fig. 1. Non-MV: intensive care unit without mechanical ventilation and acute care, MV: intensive care unit with mechanical ventilation
Example 2 Results. Predicted sojourn times and mortality for patients in data example from Grein et al. [9] at 28 days of follow-up. Start: time of treatment initiation, Non-MV: noninvasive positive pressure ventilation, nasal high-flow oxygen therapy, low-flow oxygen, and ambient air, MV: ECMO and MV (): 95% confidence interval for duration estimates, (): standard error for risk estimates
| 53 patients with severe COVID-19 treated with Remdesivir (Grein et al.), results at day 28 | ||||
|---|---|---|---|---|
| Non-MV Duration in Days | MV Duration in Days | Total Length of ICU Stay in Days | Death Risk | |
| Start Non-MV | 16.26 (13.87, 18.56) | 1.41 (0.27, 2.96) | 17.67 (14.14, 21.52) | 6.2% (3.3) |
| Start MV | 6.14 (3.86, 8.41) | 14.57 (11.99, 17.31) | 20.71 (15.85, 25.72) | 19.8% (6.4) |
| Full Cohort | 9.77 (7.76, 11.81) | 9.85 (7.68, 12.14) | 19.62 (15.44, 23.95) | 15.0% (5.3) |
Fig. 3Example 2 Plot. Stacked probability plot for the data from example 2 [9] using the model in Fig. 1. Non-MV: noninvasive positive pressure ventilation, nasal high-flow oxygen therapy, low-flow oxygen, and ambient air. MV: extracorporeal membrane oxygenation and invasive mechanical ventilation
Fig. 4Example 2 Plot, Non-Ventilated vs. Ventilated on Day 0. Stacked probability plots for the data from example 2 [9] using the model in Fig. 1. Plots illustrate the clinical progression of patients who were not invasively ventilated at treatment initiation (left plot) and those who were (right plot). Non-MV: noninvasive positive pressure ventilation, nasal high-flow oxygen therapy, low-flow oxygen, and ambient air. MV: extracorporeal membrane oxygenation and invasive mechanical ventilation